Are you Dr. Tolar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 13 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
# YPB-3
New Haven, CT 06519Phone+1 203-785-4085
Summary
- Dr. Martin Tolar, MD is a neurologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and Massachusetts.
Education & Training
Boston University Medical CenterResidency, Neurology, 1998 - 2001
Charles University in Prague Faculty of MedicineClass of 1991
Certifications & Licensure
MA State Medical License 1999 - 2026
CT State Medical License 2002 - 2007
Publications & Presentations
PubMed
- 17 citationsAPOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline.Susan Abushakra, Anton P. Porsteinsson, Marwan N. Sabbagh, Luc Bracoud, Joël Schaerer
Alzheimer's & Dementia. 2020-01-01 - 1 citationsCorrection to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Hu...John A Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power
CNS Drugs. 2018-12-01 - 23 citationsDiscovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.John A Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power
CNS Drugs. 2018-09-01
Press Mentions
Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease ConferenceNovember 22nd, 2022- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s DiseaseSeptember 20th, 2022
- Alzheon Appoints Glenn Pauly as Head of CommercialSeptember 20th, 2022
- Join now to see all
